Resolution of macular oedema in Coats' disease with intravitreal bevacizumab

Article

A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two metres of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular oedema as well as tumour-like telangiectatic vessels and exudation in temporal periphery.

A 13-year-old boy was referred because of visual deterioration in his right eye. The visual acuity was two metres of counting fingers. Indirect ophthalmoscopy and biomicroscopy revealed exudative macular oedema as well as tumour-like telangiectatic vessels and exudation in temporal periphery. With diagnosis of Coats' disease (stage II) confirmed by fluorescein angiography, three intravitreal injections of bevacizumab were performed at 6-week intervals. One year after the last injection, there was a significant resolution of macular oedema as well as visual acuity improvement to 20/20. This is the first case report in which a distinct improvement in macular oedema was observed with intravitreal bevacizumab in Coats' disease.

To read the full case click here

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
© 2025 MJH Life Sciences

All rights reserved.